A detailed history of Commonwealth Equity Services, LLC transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Commonwealth Equity Services, LLC holds 46,933 shares of CRBU stock, worth $135,167. This represents 0.0% of its overall portfolio holdings.

Number of Shares
46,933
Previous 59,964 21.73%
Holding current value
$135,167
Previous $76,000 43.42%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 22, 2025

SELL
$1.24 - $2.48 $16,158 - $32,316
-13,031 Reduced 21.73%
46,933 $109,000
Q2 2025

Aug 06, 2025

SELL
$0.73 - $1.42 $978 - $1,902
-1,340 Reduced 2.19%
59,964 $76,000
Q1 2025

May 09, 2025

BUY
$0.88 - $1.88 $2,805 - $5,993
3,188 Added 5.49%
61,304 $56,000
Q4 2024

Feb 10, 2025

BUY
$1.59 - $2.79 $1,364 - $2,393
858 Added 1.5%
58,116 $92,000
Q3 2024

Oct 18, 2024

BUY
$1.56 - $2.73 $1,726 - $3,022
1,107 Added 1.97%
57,258 $112,000
Q2 2024

Jul 31, 2024

BUY
$1.62 - $5.05 $10,726 - $33,436
6,621 Added 13.37%
56,151 $92,000
Q1 2024

Apr 29, 2024

SELL
$4.82 - $8.26 $2,916 - $4,997
-605 Reduced 1.21%
49,530 $255,000
Q4 2023

Feb 06, 2024

BUY
$3.58 - $6.25 $65,997 - $115,218
18,435 Added 58.15%
50,135 $287,000
Q3 2023

Oct 23, 2023

BUY
$4.08 - $8.14 $612 - $1,221
150 Added 0.48%
31,700 $152,000
Q2 2023

Aug 10, 2023

BUY
$4.04 - $5.47 $28,987 - $39,247
7,175 Added 29.44%
31,550 $134,000
Q1 2023

May 11, 2023

BUY
$4.3 - $7.78 $9,030 - $16,338
2,100 Added 9.43%
24,375 $129,000
Q4 2022

Feb 07, 2023

SELL
$5.57 - $11.01 $557 - $1,101
-100 Reduced 0.45%
22,275 $139,000
Q3 2022

Nov 14, 2022

BUY
$5.34 - $12.79 $32,760 - $78,466
6,135 Added 37.78%
22,375 $236,000
Q2 2022

Jul 19, 2022

BUY
$5.1 - $9.74 $82,824 - $158,177
16,240 New
16,240 $88,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $175M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.